AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 1.32 |
Market Cap | 223.13M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.8 |
PE Ratio (ttm) | -1.66 |
Forward PE | n/a |
Analyst | Buy |
Ask | 1.33 |
Volume | 1,263,111 |
Avg. Volume (20D) | 1,711,508 |
Open | 1.43 |
Previous Close | 1.42 |
Day's Range | 1.30 - 1.43 |
52-Week Range | 1.03 - 2.85 |
Beta | undefined |
About ATAI
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modul...
Analyst Forecast
According to 4 analyst ratings, the average rating for ATAI stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 652.05% from the latest price.
Next Earnings Release
Analysts project revenue of $250.00K, reflecting a 1.29K% YoY growth and earnings per share of -0.15, making a 25.00% increase YoY.
4 days ago · proactiveinvestors.com
atai Life Sciences announces leadership appointments to advance psychedelic therapeutics pipelineatai Life Sciences (NASDAQ:ATAI, ETR:9VC) has announced several key leadership appointments to advance its aim of delivering innovative mental health therapies. Dr Srinivas Rao has officially transiti...
2 months ago · proactiveinvestors.com
atai Life Sciences shares set to be lifted by 2025 trial data readouts: analystsatai Life Sciences (NASDAQ:ATAI, ETR:9VC) shares should move higher on a slew of Phase 2 and 3 data readouts in 2025 from across its pipeline of innovative psychedelic therapies, analysts at Jefferies...
2 months ago · proactiveinvestors.com
atai Life Sciences advances therapeutic pipeline in Q3 with FDA approval of VLS-01atai Life Sciences (NASDAQ:ATAI, ETR:9VC), a biopharmaceutical company targeting mental health disorders, advanced its pipeline of innovative therapies during the third quarter of 2024. Notably, the U...
2 months ago · proactiveinvestors.com
RFK Jr's appointment in health could accelerate psychedelic drug development, analysts sayPresident-elect Donald Trump's promise that Robert F Kennedy Junior (RFK Jr) will take on a “big role” in shaping health policy could be a positive for psychedelics given RKF Jr's well-documented supp...